• ホーム
  • 検索結果
  • Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation.

Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation.

The Journal of investigative dermatology (2014-04-18)
Todd D Prickett, Brad J Zerlanko, Victoria K Hill, Jared J Gartner, Nouar Qutob, Jiji Jiang, May Simaan, John Wunderlich, J Silvio Gutkind, Steven A Rosenberg, Yardena Samuels
要旨

The ionotropic glutamate receptors (N-methyl-D-aspartate receptors (NMDARs)) are composed of large complexes of multi-protein subunits creating ion channels in the cell plasma membranes that allow for influx or efflux of mono- or divalent cations (e.g., Ca(2+)) important for synaptic transmissions, cellular migration, and survival. Recently, we discovered the high prevalence of somatic mutations within one of the ionotropic glutamate receptors, GRIN2A, in malignant melanoma. Functional characterization of a subset of GRIN2A mutants demonstrated a loss of NMDAR complex formation between GRIN1 and GRIN2A, increased anchorage-independent growth in soft agar, and increased migration. Somatic mutation of GRIN2A results in a dominant negative effect inhibiting the tumor-suppressive phenotype of wild-type (WT) GRIN2A in melanoma. Depletion of endogenous GRIN2A in melanoma cells expressing WT GRIN2A resulted in increased proliferation compared with control. In contrast, short-hairpin RNA depletion of GRIN2A in mutant cell lines slightly reduced proliferation. Our data show that somatic mutation of GRIN2A results in increased survival, and we demonstrate the functional importance of GRIN2A mutations in melanoma and the significance that ionotropic glutamate receptor signaling has in malignant melanoma.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
モノクロナール抗シナプトフィジン マウス宿主抗体, clone SVP-38, ascites fluid
Sigma-Aldrich
Anti-GAPDH Mouse mAb (6C5), liquid, clone 6C5, Calbiochem®
Sigma-Aldrich
抗シナプトフィジン抗体, マウスモノクローナル, clone SVP-38, purified from hybridoma cell culture
Sigma-Aldrich
Anti-p38 MAPK antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Monoclonal Anti-MAP Kinase 2 (ERK-2) antibody produced in mouse, clone 1B3B9, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Anti-MAPK14 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
抗シナプトフィジン ウサギ宿主抗体, affinity isolated antibody
Sigma-Aldrich
Anti-p38 MAPK antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-p38 MAPK antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-MAPK14 (Ab-182) antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
抗SYP抗体 ウサギ宿主抗体, affinity isolated antibody
Sigma-Aldrich
Anti-MAPK14 antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
抗SYP抗体 ウサギ宿主抗体, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
Anti-MAP Kinase 2 (ERK-2) antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution, ~1 mg/mL
Sigma-Aldrich
Anti-p38 MAP Kinase antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution

ソーシャルメディア

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

研究、開発、製造

私たちは、バイオテクノロジーと医薬品の研究&開発および製造のソリューションとサービスを提供する、グローバルなライフサイエンス業界のリーディングサプライヤーです。

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates.All Rights Reserved.

当ウェブサイトのいかなる内容についても、許可なく複写することを禁じます。